Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden

Bogdanovic, Nenad ; Hansson, Oskar LU orcid ; Zetterberg, Henrik LU ; Basun, Hans ; Ingelsson, Martin ; Lannfelt, Lars and Blennow, Kaj LU (2020) In Läkartidningen 117.
Abstract

Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients.... (More)

Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients. The latest clinical development of potential therapy for Alzheimer's is active or passive immunotherapy against brain β-amyloid and tau, where several studies have shown varying but promising treatment effects. Non-pharmacological interventions in patients with AD aim to delay the loss of mental abilities, helping people to be independent in everyday life for as long as possible, and to increase their well-being and quality of life.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
alternative title
Alzheimer's disease - the most common cause of dementia
publishing date
type
Contribution to journal
publication status
published
subject
in
Läkartidningen
volume
117
article number
FZHM
publisher
Swedish Medical Association
external identifiers
  • scopus:85081945477
  • pmid:32154904
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
da74600a-c228-464d-a33d-154ee3aa8230
alternative location
https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/temaartikel/2020/03/alzheimers-sjukdom-diagnostik-och-behandling-i-dag-och-i-framtiden/
date added to LUP
2021-01-12 10:42:23
date last changed
2024-06-27 06:51:19
@article{da74600a-c228-464d-a33d-154ee3aa8230,
  abstract     = {{<p>Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients. The latest clinical development of potential therapy for Alzheimer's is active or passive immunotherapy against brain β-amyloid and tau, where several studies have shown varying but promising treatment effects. Non-pharmacological interventions in patients with AD aim to delay the loss of mental abilities, helping people to be independent in everyday life for as long as possible, and to increase their well-being and quality of life.</p>}},
  author       = {{Bogdanovic, Nenad and Hansson, Oskar and Zetterberg, Henrik and Basun, Hans and Ingelsson, Martin and Lannfelt, Lars and Blennow, Kaj}},
  issn         = {{0023-7205}},
  language     = {{swe}},
  month        = {{03}},
  publisher    = {{Swedish Medical Association}},
  series       = {{Läkartidningen}},
  title        = {{Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden}},
  url          = {{https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/temaartikel/2020/03/alzheimers-sjukdom-diagnostik-och-behandling-i-dag-och-i-framtiden/}},
  volume       = {{117}},
  year         = {{2020}},
}